Chemotherapy, Radiotherapy and Bevacizumab in Patients With Unresectable Stage III Non-Small-Cell Lung Cancer

Phase 2 Terminated 5 enrolled SCRI Development Innovations, LLC Eli Lilly and Company · collab Genentech, Inc. · collab

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to see if this combination of chemotherapy plus radiation therapy and immunotherapy (with bevacizumab) expands treatment options for patients with non-small cell lung cancer.

Timeline

Start: 2006-11
Primary completion: 2009-01
Completion: 2009-01

Outcome

Outcome not reported

Stopped: “Terminated due to bevacizumab and chemoradiotherapy toxicity”

Publications

Results Spigel DR, Hainsworth JD, Yardley DA, Raefsky E, Patton J, Peacock N, Farley C, Burris HA 3rd, Greco FA. Tracheoesophageal fistula formation in patients with lung cancer treated with chemoradiation and bevacizumab. J Clin Oncol. 2010 Jan 1;28(1):43-8. doi: 10.1200/JCO.2009.24.7353. Epub 2009 Nov 9.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Bevacizumab	Monoclonal antibody	15 mg/kg	Intravenous
Subject	Carboplatin	Small molecule	—	Intravenous
Subject	Pemetrexed	Small molecule	500 mg/m2	Intravenous